Skip to content
Low Dose GLP-1Providers

Provider review

Pallas Health review

Documents itself better than anyone here, and sells no low dose you can buy.

Six dispensing pharmacies and two registry-verified clinicians named in public — over a twelve-week prepay, with no dose selector anywhere before purchase and no tier beneath the full dose.

Reviewed by Lena OrtizMetabolic Health Editor

Price updated August 2026

How we’re funded. Some links here are affiliate links: start care through one and we may earn a commission, at no extra cost to you. Affiliate partners are listed first on our rankings — what we write about a provider is the same either way, and unflattering findings about one that pays us stay in. Full disclosure.

Price as published

Pallas Health

$199/mo sema · $299/mo tirz (12-wk prepay)

Vs median
$30/mo above the $169 median
Market
$59–$1300/mo across 242 of 373
Structure
Standard plan, self-directed low dose
Dispensed
Compounded, unnamed partner network

Advertising disclosure · we may earn a commission if you start care through some of these links, at no extra cost to you.

In one paragraph

The verdict

Start with what this is not, because it is the only thing that decides whether the rest matters to you: Pallas sells full-dose compounded semaglutide and full-dose compounded tirzepatide, and nothing underneath them. There is no low-dose product, no microdose tier and no dose selector anywhere before you pay, so starting small here means asking for less inside a full-dose plan and being billed the full-dose plan's price. If that is the whole reason you are reading this site, this is a walk-past, and none of the rest changes it. The second thing to understand is the billing, because the advertised monthly figure is not a monthly figure — it is a twelve-week prepay divided by three, and no month-to-month option is published for either molecule. The shape catches people rather than the size: a small introductory payment, then the full quarterly charge in one go four weeks later. And twelve weeks is not three months, so a renewal anchored to an eighty-four-day cycle comes round more often in a year than dividing by three implies, which leaves the advertised average an understatement of what the plan costs to hold. What Pallas then does better than almost anything else here is prove who it is. It names six dispensing pharmacies outright and explains the difference between the two pharmacy categories, where the norm here is to name none. It names two prescribing clinicians with their registry numbers and links the federal registry so you can check them yourself. Its certification seal resolves against the certifier's own host rather than being an image anyone could paste. The price the marketing quotes is the price the checkout charges, cancellation is self-serve with a reminder before each renewal and no minimum term, and a clinician turning you down refunds you in full. Its FAQ also promises that the price does not climb as the dose does, which is exactly the commitment this site's reader wants in writing — and it is the one claim here that could not be checked, because with no dose selector before purchase there is nothing to test it against. Both halves belong in the same sentence: the promise is theirs, the verification is nobody's.

Visit Pallas Health

Microdosing is off-label and unproven — decide with a clinician. Prices are as published by the provider when we last checked; confirm current terms before you buy.

Who it suits, and who it does not

A good fit if

  • You have decided on a full therapeutic dose and want the company behind it to be checkable — the dispensing pharmacies named, the prescribing clinicians named, the certification seal resolvable
  • You want to know which pharmacy is filling your prescription before you order, and have kept running into sites that will not say
  • You are comfortable prepaying a quarter at a time and would rather have one larger charge than a monthly one
  • You want a documented way out before you are in: a cancellation portal you operate yourself, a reminder before each renewal, no minimum term, and a full refund if a clinician declines you
  • You live in one of the states where the whole intake is asynchronous and would rather not book a video visit

Look elsewhere if

  • You came here to pay less for taking less — there is no low-dose tier to buy, no dose selector before purchase, and a smaller dose is billed at the full plan's price
  • You want to pay month to month, or to compare a genuine monthly rate against the other providers here: the advertised figure is a quarterly prepay divided by three, and no monthly rung is published for either molecule
  • Your budget cannot absorb the second charge, which arrives as the full quarterly amount four weeks after a much smaller first one
  • You want the flat-price-at-every-dose promise demonstrated rather than stated — nothing public here lets it be tested
  • You want lab work costed before you commit, or an independent review record to weigh against the company's own figures; neither is published

What it actually costs

Price as published

Compounded semaglutide advertised at $199/mo average — in practice $597 billed every 12 weeks, after $139 for the first 4 weeks · compounded tirzepatide advertised at $299/mo average — $897 billed every 12 weeks, after $179 for the first 4 weeks · no month-to-month rung is published for either molecule, and no dose selector appears anywhere before purchase · brand-name cash-pay, genuinely billed monthly: Zepbound® $1,069/mo · Ozempic® $1,299/mo · Wegovy® $1,349/mo · Mounjaro® $1,349/mo · cash-pay only, no insurance, FSA/HSA eligible per the site banner

Vs median
$30/mo above the $169 median across the 242 of 373 programs we track that publish a plain monthly rate
Market
$59–$1300/mo is the full published spread in our ranking
Structure
Standard plan, self-directed low dose

No low-dose product of its own. Starting low means asking for a smaller amount inside a standard plan, at the standard plan's price.

152 of the 373 programs we track price a small dose this way. The row states that no low-dose or microdose product is purchasable on any screen or by any walked path, and that no dose selector appears before purchase — so starting low here means self-directing inside a full-dose plan at the full-dose plan's price. Both molecules do carry a figure readable before intake, but the row records that figure as a twelve-week prepay divided by three rather than a rate anyone is billed, and carries the twelve-week condition alongside it everywhere it prints. The company's own claim that price does not rise with dose is recorded on the row and deliberately not scored here, because the missing dose selector is precisely what makes it untestable.

Visit Pallas Health

Microdosing is off-label and unproven — decide with a clinician. Prices are as published by the provider when we last checked; confirm current terms before you buy.

What is included

Consult
Included in the price
Dietitian
Not included
Labs
Optional
Pricing
Varies by dose, plan or tier
Price last updated
August 2026

What it does well

  • Names SIX dispensing pharmacies publicly — Belmar, Strive, Epiq Scripts, Casa Pharma Rx, The Pharmacy Hub and Foothills — with the 503A/503B distinction explained, where most rows here name none
  • Names two prescribing clinicians with their NPI numbers and links the NPPES registry to check them: Dr. Ana Lisa Carr, MD (NPI 1689841744, active, family medicine, licensed in 15 states) and Dr. Kelly Tenbrink, MD (NPI 1346482684, active, emergency medicine, licensed in TN and FL). The site additionally claims obesity- and addiction-medicine certification for Dr. Carr, which the NPPES registry does not cover either way
  • LegitScript Healthcare Merchant Certified, with a seal ID that resolves against LegitScript's own host rather than an image anyone could copy
  • The advertised price is the price the checkout charges — the homepage FAQ, the landing pages, the treatment pages and the live funnel all state the same figures, so nothing changes at the last screen
  • A real self-serve exit: a cancellation portal you operate yourself, a pre-renewal email reminder, no minimum term, cancellation free and effective at the end of the current billing period, and at least 30 days' notice before any price change
  • Prescribes in all 50 states and DC, fully asynchronous in 43 of them, with a full refund if a clinician declines you and free shipping once a prescription is written
  • Its FAQ states that the price does not rise as the dose does — the single commitment a titrating reader most wants in writing, though nothing public lets it be tested (see below)

Pharmacy, labs and oversight

Pallas Health dispenses through a Network facility. Bloodwork is offered but not required. A clinician review is included in the price.

Transparency check

3 of 4 published openly

What Pallas Health publishes about itself, read from its own pages when we verified them — not estimated, and not a score.

Pharmacy named and regulatedAn unnamed partner network — regulated, but the pharmacy itself is not identified.
Published
A price you can read before intakeA monthly rate is published on its own pages — the figure in the price row above, read there and verified against it.
Published
What a higher dose costsPriced by dose, plan or tier, and the higher rungs are not published — the advertised figure does not tell you what a larger dose costs.
Not published
No FDA warning letter on fileChecked against the FDA's own warning-letter database; nothing on file for this company.
None on file

How the program works

Pallas Health (pallashealth.co) is operated by Brentmoor, Inc. of Newark, Delaware, with clinical care delivered by Lion MD — a nationwide team of US-licensed clinicians — on the CareValidate clinical-operations platform. Pallas states plainly that it is a technology platform and does not employ medical providers. An online intake is reviewed asynchronously in 43 states; seven states (Arkansas, Mississippi, New Mexico, North Dakota, Rhode Island, South Dakota and West Virginia) plus Washington DC require one video visit. It prescribes in all 50 states and DC, cash-pay only and never through insurance, with free shipping once a prescription is written. The catalog a buyer can actually reach is narrow: full-dose compounded semaglutide and full-dose compounded tirzepatide as weekly injections, alongside a brand-name pathway, and no low-dose or microdose product of any kind is purchasable through the funnel. Billing is the thing to understand before comparing this with anything else here — an introductory first period, then a single prepaid charge recurring every twelve weeks and anchored four weeks after approval, with the advertised monthly figure being that quarterly charge divided by three rather than a rate anyone is billed. The checkout is genuinely instrumented: Stripe Elements, Klarna pay-over-time, a promo-code field, a shipping-state eligibility guard, a self-serve cancellation portal, a pre-renewal email reminder, no minimum term, cancellation free and effective at the end of the current billing period, at least 30 days' notice before any price change, and a full refund if a clinician declines you.

The honest cons

There is no purchasable low-dose or microdose tier here — not on any screen, at any rung, by any path that was walked — and no dose selector appears anywhere before purchase. Pallas sells full-dose compounded semaglutide and full-dose compounded tirzepatide and nothing beneath them, so starting small means asking for less inside a full-dose plan and paying the full-dose plan's price
  • The advertised "/mo average" is a twelve-week prepay divided by three, not a rate anyone is billed: there is no month-to-month rung for either molecule, and the funnel renders no cadence selector at all. The likeliest bill shock is the shape rather than the size — a $139 first payment, then $597 in one go four weeks later
  • Twelve weeks is not three months. The renewal recurs every 84 days, which is 4.35 times a year rather than 4, while the advertised average divides by 3 — so on the company's own published terms the advertised figure understates the ongoing rate by about 8.7%
  • The flat-price-at-every-dose promise could not be tested, because there is no pre-purchase dose selector to test it with — the one commitment that would matter most to a low-dose reader rests here on the company's word alone
  • One of the six named dispensing pharmacies, Belmar, received an FDA warning letter over compounding practices, issued 03/31/2023 and addressed to "Belmar Pharma Solutions, Drug Depot, LLC., dba APS Pharmacy" — FDA closed that letter out on 10/30/2023. Pallas itself carries no warning letter
  • Only two clinicians are named site-wide. The prescribing network itself — Lion MD's affiliated professional corporations — is not published, and the footer's "Provider directory" link resolves to a section naming the same two people
  • The site's own footer states that some of its content is AI-generated and makes no representation as to its accuracy, so its blog is not a source to take a clinical claim from; the advertised 4.8 rating has no published source; and the before-and-after "Verified Customer" stories carry the caveat that individuals shown in marketing may be actors or models
  • Two charges sit outside the headline figures: in the seven video-visit states and DC a $60 visit deposit may be retained if you neither attend nor reschedule and then abandon the intake (otherwise it is refunded in full and credited to your first order), and a $5 fee is deducted per refunded payment on purchases made on or after July 14, 2026 — never on clinician-declined or unfulfilled orders, which refund in full
  • Whether baseline or follow-up lab work is included or charged on top is not published anywhere, and no Trustpilot or BBB record corroborates the company's own figures
  • No insurance, ever — and its brand-name pathway runs $1,069–$1,349 a month, far above what an insured patient pays for the same drugs
  • It launched on this affiliate network on 1 July 2026, so the public record behind all of the above is short
  • Compounded GLP-1s are not FDA-approved and are not generic equivalents of the brand drugs, and intentional microdosing is off-label and unproven — Pallas discloses the first properly, and the second is moot here because it sells no microdose
Visit Pallas Health

Microdosing is off-label and unproven — decide with a clinician. Prices are as published by the provider when we last checked; confirm current terms before you buy.

How it compares

Pallas Health is one of 373 low-dose GLP-1 programs we track, and 242 of them publish a monthly rate you can read before signing up. The ranking lists every published price on one screen, ordered with the companies that pay us first — a mechanism we state there, on the page it applies to.

Where this sits

#24 of 373

Ordered with the companies that pay us first, and Pallas Health is one of them. A disclosed partition, not a score.

Compare all 373 providers →

Read this before you buy

Intentional GLP-1 microdosing is off-label and unproven — no randomized trial has established that a sub-label dose does anything, and any dose belongs with a clinician who knows your history. If you are going to have that conversation, have it with real numbers.

Visit Pallas Health

Microdosing is off-label and unproven — decide with a clinician. Prices are as published by the provider when we last checked; confirm current terms before you buy.

The closest alternative

RxSpan MD

From $194/mo

Vs median
$25/mo above the $169 median
Market
$59–$1300/mo across 242 of 373
Structure
Standard plan, self-directed low dose
Dispensed
Pharmacy not publicly identified

Advertising disclosure · we may earn a commission if you start care through some of these links, at no extra cost to you.

Read the RxSpan MD review →

Microdosing is off-label and unproven — decide with a clinician. Prices are as published by the provider when we last checked; confirm current terms before you buy.